试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-04
Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease
编号:NCT05670912登记状态:提前终止企业 / 申办者:Capital Medical University
药物 / 成分:Wei Li Bai capsules、Placebo Comparator of Wei Li Bai capsules
登记的停止原因(原文):Due to the inability to complete subject enrollment and follow-up as originally scheduled, coupled with funding shortages and overall strategic adjustments from the sponsor, the study was terminated on November 12, 2024.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-04
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
编号:NCT06290388登记状态:提前终止企业 / 申办者:23andMe, Inc.
药物 / 成分:23ME-01473
登记的停止原因(原文):Sponsor cancelled study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-04
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
编号:NCT06567002登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:MK-6552
登记的停止原因(原文):Business Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
编号:NCT02867839登记状态:提前终止企业 / 申办者:Peking University Cancer Hospital & Institute
药物 / 成分:Oxaliplatin plus S-1、S-1 only
登记的停止原因(原文):The number of patients enrolled was much less than expected
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation
编号:NCT03750656登记状态:提前终止企业 / 申办者:University of Kansas Medical Center
药物 / 成分:Hyoscyamine、Tamsulosin
登记的停止原因(原文):Not accruing patients quickly enough
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD
编号:NCT04269850登记状态:提前终止企业 / 申办者:St. Petersburg State Pavlov Medical University
药物 / 成分:allogeneic fecal microbiota、Ruxolitinib、Methylprednisone
登记的停止原因(原文):Poor recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
编号:NCT04515797登记状态:提前终止企业 / 申办者:Massachusetts General Hospital
药物 / 成分:Glecaprevir and Pibrentasvir
登记的停止原因(原文):Unable to meet enrollment goal prior to drug expiration
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
编号:NCT05096884登记状态:提前终止企业 / 申办者:Hackensack Meridian Health
药物 / 成分:Metoprolol Succinate
登记的停止原因(原文):Low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
编号:NCT05458102登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:Vesatolimod、Cobicistat、Voriconazole、Rifabutin
登记的停止原因(原文):Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
CD8 Minibody Repeatability Study
编号:NCT05744128登记状态:提前终止企业 / 申办者:ImaginAb, Inc.
药物 / 成分:Zirconium 89Zr crefmirlimab berdoxam
登记的停止原因(原文):Strategic decision
查看官方原始记录 ↗